Provided by Tiger Trade Technology Pte. Ltd.

Zenas BioPharma Inc.

31.10
-1.1900-3.69%
Volume:646.94K
Turnover:20.20M
Market Cap:2.03B
PE:-3.44
High:31.89
Open:31.88
Low:30.73
Close:32.29
52wk High:44.60
52wk Low:13.50
Shares:65.18M
Float Shares:47.02M
Volume Ratio:1.27
T/O Rate:1.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.0522
EPS(LYR):-8.4448
ROE:-199.04%
ROA:-34.42%
PB:8.20
PE(LYR):-3.68

Loading ...

Zenas Biopharma announces underwritten public offering of convertible senior notes due 2032; terms are set at pricing

Reuters
·
Mar 27

Zenas Biopharma Inc - Proceeds to Support Obexelimab U.S. Launch, Pipeline Advancement, and General Corporate Purposes

THOMSON REUTERS
·
Mar 27

Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock

GlobeNewswire
·
Mar 27

Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Progressive Multiple Sclerosis

TIPRANKS
·
Mar 21

Wedbush Sticks to Its Buy Rating for Zenas BioPharma, Inc. (ZBIO)

TIPRANKS
·
Mar 17

Zenas BioPharma Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
Mar 17

Zenas BioPharma Price Target Maintained With a $44.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 17

Zenas BioPharma: De‑Risked Autoimmune Late‑Stage Assets and Strong Balance Sheet Underpin Buy Rating and $44 Target

TIPRANKS
·
Mar 17

Zenas BioPharma price target lowered to $41 from $43 at Citi

TIPRANKS
·
Mar 17

IPO-Related Securities Class Action Poses Ongoing Financial and Operational Risks for Zenas BioPharma

TIPRANKS
·
Mar 17

Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Mar 17

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 17

Zenas BioPharma Inc. Announces Annual Stockholders Meeting

Reuters
·
Mar 16

Earnings Flash (ZBIO) Zenas BioPharma Posts Q4 Net Loss $4.54 a Share

MT Newswires Live
·
Mar 16

Zenas BioPharma Q4 EPS $(4.54) Down From $(1.26) YoY

Benzinga Earnings
·
Mar 16

Zenas BioPharma Q4 net loss rose 357% to USD 240.44 million

Reuters
·
Mar 16

Press Release: Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Mar 16